Vyvron Review: It Tells You Exactly What It Is, and Nothing About What Is In the Vial
Vyvron is refreshingly clear about one thing and silent about another, and the two are related. It states plainly that it is "a marketing and customer-acquisition platform," not a provider or a pharmacy, and it names the medical group that treats you. Then it sells injectable sermorelin at $229 — a molecule whose newest randomised trial anywhere in the literature was published in 2005 — and its entire published site, all 483,328 characters of it, contains not one instance of the words sterility, potency, USP, tested or certificate of analysis. Its own guide tells readers how to check a provider is legitimate. It does not pass the part of that test about what is in the vial.
Dispenses
Compounded only
Evidence
Phase 3 trials
Pharmacy
Not named
FDA letter
None found
By Grant Delaney, Research Editor·
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens vyvron.com. A link is not a recommendation to take anything.
Provenance
What Vyvron actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Compounded (503A)5 products
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Injectable Sermorelin — $229 a month as listed on the product tile — though the same page's hero sells the programme at "$189 / 4 weeks" founding, reverting to $229, so the unit behind this figure is not consistent across one page.
Injectable NAD+ — $229 a month on the product tile; the programme hero prices the same thing at $189 per four weeks founding.
Injectable B12-MIC — $145 a month on the product tile — also the figure the /programs page gives as the whole longevity programme's starting price.
Compounded semaglutide (weight management programme) — $199 every four weeks as a founding member, reverting to $249. Thirteen charges a year, not twelve. Medication is included per the cancellation policy.
Microdose programme (low-dose GLP-1 combinations) — $149 every four weeks founding, reverting to $179 — though the /programs page lists this programme at "Starting at $179/mo" on the same day.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
Sermorelin · cmpd
No human trial
NAD+ · cmpd
No human trial
B12-MIC · cmpd
No human trial
Semaglutide · cmpd
Phase 3 trials
Semaglutide or tirzepatide, low-dose · cmpd
No human trial
1
Products with a human trial
Out of 5 reviewed here.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Vyvron’s own page, with the page it came from. Grading a paraphrase would prove nothing.
Injectable Sermorelin
No trial supports this claim
“Injectable Sermorelin $229/mo — Physician-prescribed GHRH peptide. Clinician-supervised program. Compounded; not FDA-approved… Wellness and healthy-aging support — options like NAD+, Sermorelin, and B12-MIC — for energy, cellular health, and vitality, when clinically appropriate.”
As of August 2026, a PubMed search for sermorelin filtered to the randomised-controlled-trial publication type returned 19 records, and the most recent of the 19 was published in 2005 — a study of a PEG-conjugated GHRH analogue measuring growth hormone stimulation in healthy young and elderly subjects. Reading the set, every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures energy, cellular health or "vitality" as an outcome in healthy adults. A parallel search of ClinicalTrials.gov for sermorelin as an intervention returned 27 studies.
Vyvron's wording is careful and its regulatory labelling is correct — it calls sermorelin a GHRH peptide, says it is compounded, and says it is not FDA-approved, all in the product tile. What it sells the peptide for is "energy, cellular health, and vitality," and that is where the evidence runs out. Sermorelin does stimulate pituitary growth hormone release; that is a mechanism, and it is the reason the molecule existed, largely as a diagnostic agent. The most recent randomised trial in the entire literature is more than twenty years old and measured GH secretion, not how anyone felt.1,2
Injectable NAD+
No trial supports this claim
“Injectable NAD+ $229/mo — Physician-prescribed and clinician-supervised. Compounded; not FDA-approved… A guided path to NAD+ — your founding rate is locked for as long as you're a member.”
As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" in the title or abstract, combined with an injected route (subcutaneous, injection or intravenous) and filtered to the randomised-controlled-trial publication type, returned exactly one record: a 2026 placebo-controlled trial of NAD+ in heart failure caused by ischaemic cardiomyopathy. Removing the route filter raises the count to 70 records, none testing an injectable preparation for the uses sold here. A parallel ClinicalTrials.gov search for NAD+ as an intervention returned 261 studies, across conditions including lupus, mild cognitive impairment, hepatitis C and pulmonary hypertension.
Vyvron makes less of a claim here than most sellers of this product do — the tile is essentially a name, a price and a regulatory disclosure, and the surrounding page sells "energy, cellular health, and vitality" for the category rather than for this molecule specifically. That restraint is worth noting. It does not change that the outcome being sold has one randomised injected-route trial behind it, in a cardiac population, and that the buyer is paying $229 for it.3
Injectable B12-MIC
No trial supports this claim
“Injectable B12-MIC $145/mo — Methylcobalamin + MIC support injection. Physician-guided. Compounded; not FDA-approved.”
Methylcobalamin with methionine, inositol and choline (B12-MIC) · Compounded (503A) · read August 2026
No human trial
As of August 2026, a PubMed search for methionine, inositol and choline together, filtered to the randomised-controlled-trial publication type, returned zero records — not a weak literature, an empty one for the combination as such. Searching the term the category uses instead, lipotropic, returned six randomised trials, and ClinicalTrials.gov listed one study with lipotropic as an intervention. The three amino compounds in a MIC injection are each individually studied; the injected blend sold under this name has not been through a registered trial.
This is the least-discussed product in the category and the one with the thinnest evidence base. Vyvron's tile makes almost no claim — "support injection" is doing the work — but it sits under a programme heading selling "energy, cellular health, and vitality" at $145 a month, and there is no randomised trial of the combination at all. B12 repletion in someone actually deficient is real medicine; that is not what is being sold at a flat monthly subscription price to an unselected buyer.4
“Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before they are marketed, and they are not identical or equivalent to any FDA-approved branded medication. Vyvron does not imply any such equivalence.”
NCT03548935STEP 1 — Phase 3, completed, n=1,961. Tested the approved once-weekly 2.4 mg product in adults with overweight or obesity. No compounded semaglutide preparation has been through a registered trial.
The disclaimer is accurate, it is repeated in the footer of every page rather than buried on one, and the final sentence — "Vyvron does not imply any such equivalence" — is a refusal rather than a hedge. On the GLP-1s Vyvron claims nothing the molecule's trials do not support, which makes the silence on its peptide line stand out rather than blend in.5
Microdose programme (low-dose GLP-1 combinations)
No trial supports this claim
“A lighter, low-dose approach. Microdose combinations pair low-dose GLP-1 medication with supportive ingredients for metabolic support and energy, when clinically appropriate… A measured starting point — for those not ready for full-dose treatment.”
Semaglutide or tirzepatide, low-dose · Compounded (503A) · read August 2026
No human trial
As of August 2026, a PubMed search combining low-dose, microdose or microdosing with semaglutide, tirzepatide or GLP-1, filtered to the randomised-controlled-trial publication type, returned 22 records. Every one of the 22 concerns dose-ranging or titration within an approved therapeutic programme — the low arms of trials whose purpose was to reach a therapeutic dose. None tests a deliberately sub-therapeutic maintenance regimen combined with "supportive ingredients" as a distinct treatment, which is what is sold here. The compounded combination itself is not a registered intervention anywhere.
"Microdosing" a GLP-1 is a marketing construct rather than a studied regimen. The phase 3 evidence for semaglutide and tirzepatide was generated by titrating up to a target dose and holding it; a programme built on deliberately staying below that, blended with unnamed "supportive ingredients," is not the thing that was tested. Vyvron's own framing — "a measured starting point — for those not ready for full-dose treatment" — is the most defensible version of this claim, because a starting point is what the low arms of those trials actually were. It is sold as an ongoing programme at $149 every four weeks.6
Dispensing chain
Who actually fills your prescription
Pharmacy not named
Vyvron names the clinical side of its chain and none of the pharmacy side, and it is unusually direct about the distinction. Its privacy policy states: "Vyvron is a marketing and customer-acquisition platform. Telemedicine and clinical services are provided by OpenLoop Health, Inc., OpenLoop Healthcare Partners, PC, and its affiliated medical groups." Its terms add that "Vyvron LLC is a telehealth access, brand, lifecycle, and operational support platform. Vyvron is not a medical provider, pharmacy, or insurance plan." The intake form at start.vyvron.com asks the patient to agree to OpenLoop's telehealth consent by name, so the clinical entity is disclosed at the point it matters. The pharmacy is not. The strongest statements anywhere are "partner pharmacies", "a licensed pharmacy fulfills all prescriptions" and, in the privacy policy, a reference to "OpenLoop Health, Inc. and its affiliated medical groups and partner pharmacies." No pharmacy is named, no state licence number is published, and there is no way for a customer holding a vial to determine who compounded it. The corporate address, 30 N Gould St, Ste N, Sheridan, Wyoming, is a registered-agent suite rather than a clinical or dispensing site.
Nothing. This is the clearest finding on the review and it was measured rather than inferred. Vyvron's entire site — every route, every legal page, every educational article — is served from a single client bundle of 483,328 characters, read on August 7, 2026. Searched across the whole of it, the strings "USP", "sterile", "potency", "tested", "purity", "certificate of analysis", "COA", "503A", "503B" and "lot" appear zero times. Not vaguely, not in a footnote: they are absent from the code that renders the site. What Vyvron does publish about quality is regulatory-status language — that compounded medications "are not reviewed by the FDA for safety, effectiveness, or quality" — which describes what nobody has checked rather than what anybody has. The contrast with its own /learn library is sharp, because Vyvron has written a guide on how to verify a legitimate online GLP-1 provider and another on what LegitScript certification means. Its pages carry a LegitScript seal served under certificate id 50305996; LegitScript's public checker is reCAPTCHA-gated and returned no certification record when queried on August 7, 2026, so the seal is reported here as displayed rather than as confirmed.
All 50 states and Washington, D.C. for provider evaluation; compounded GLP-1s in 49 states, excluding Mississippi
Vyvron's own FAQ: "Vyvron connects patients with licensed providers in all 50 states plus Washington, D.C. Available nationwide; in certain states, evaluation requires a scheduled video visit (AR, DC, DE, KS, MS, NM, RI, WV). Compounded GLP-1 medications are not available to Mississippi residents; Mississippi residents may be eligible for branded options only. State, medication, and pricing availability may vary and can change." Every program page repeats the Mississippi carve-out in its footer. This is licensure asserted by a company that states it holds no clinical licence itself — the licences belong to OpenLoop's affiliated medical groups and to unnamed partner pharmacies, neither of which publishes a licence number through Vyvron. Nothing here was verified against a state board.
A search of the 113 warning letters issued to telehealth firms in the September 9, 2025, February 20, 2026 and June 8, 2026 enforcement waves — matched on full company name rather than substring, because a substring match attaches one company’s regulatory history to another — returns no entry for Vyvron (Vyvron LLC). That is a statement about those three waves as of August 2026, not a claim that no action exists anywhere.
Assessment
What holds up, and what does not
What holds up
It says what it is. "Vyvron is a marketing and customer-acquisition platform" is a sentence almost nobody in this category will write about themselves.
It names the clinical entity — OpenLoop Health, Inc. and OpenLoop Healthcare Partners, PC — in the privacy policy and again in the intake consent.
Every product tile carries its own regulatory label: "Compounded; not FDA-approved," next to the price rather than in a footer.
On the GLP-1s it refuses equivalence outright: compounded products "are not identical or equivalent to any FDA-approved branded medication. Vyvron does not imply any such equivalence."
The cancellation policy confirms medication and support are included in the subscription price, and shipping is free — so the advertised figure is the whole bill.
Prescribing genuinely requires review: the intake at start.vyvron.com is a real clinical questionnaire, and eight states are flagged as requiring a scheduled video visit.
What does not
There is no testing disclosure at all. Across 483,328 characters of published site code, "sterile", "potency", "USP", "tested" and "certificate of analysis" occur zero times.
No pharmacy is named anywhere — only "partner pharmacies" — so a customer has no way to learn who compounded the vial they were sent.
Injectable sermorelin is sold at $229 for "energy, cellular health, and vitality." The newest randomised sermorelin trial in the literature was published in 2005 and measured growth hormone secretion.
The B12-MIC blend has no registered trial as a combination: a search for methionine, inositol and choline together among randomised trials returned zero records.
"Microdosing" is sold as an ongoing programme, but the low arms of the GLP-1 trials were a route to a therapeutic dose, not a destination.
The listed corporate address is a registered-agent suite in Sheridan, Wyoming, and the "100 of 100 founding spots left" counter read the same on every page at every check.
Verdict
The bottom line
Vyvron is honest about its structure and silent about its substance. It will tell you it is a marketing platform, name the medical group that will treat you, label every product as compounded and not FDA-approved, and refuse to claim its compounded GLP-1s are equivalent to the branded ones. Those are real virtues and they are rarer than they should be. But it sells three injectables into a longevity programme where the evidence ranges from thin to absent — sermorelin's newest randomised trial is from 2005, injectable NAD+ has one, and the B12-MIC blend has none — and it publishes nothing at all about who tests those preparations, for what, or to what standard. Vyvron has written a guide on how to verify a legitimate online provider. On the question its own guide would ask about what is in the vial, the site returns nothing.
Opens vyvron.com. A link is not a recommendation to take anything.
What Vyvron will tell you
Start with the good, because it is unusual and it is load-bearing for everything after.
Most telehealth brands in this category work hard to look like a clinic. Vyvron does the opposite. Its privacy policy opens by saying "Vyvron is a marketing and customer-acquisition platform. Telemedicine and clinical services are provided by OpenLoop Health, Inc., OpenLoop Healthcare Partners, PC, and its affiliated medical groups." Its terms describe it as "a telehealth access, brand, lifecycle, and operational support platform" and state flatly that "Vyvron is not a medical provider, pharmacy, or insurance plan." The footer of every page repeats it.
That matters because it is checkable. A reader who knows the treating entity is OpenLoop can go and look at OpenLoop. A reader told only that "licensed providers" are involved cannot look at anything.
The product labelling is good too. Each tile on the longevity page carries its own regulatory line directly beneath the price — "Physician-prescribed GHRH peptide. Clinician-supervised program. Compounded; not FDA-approved." On the weight-management side, the disclaimer goes further than most and ends in a refusal rather than a hedge: compounded medications "are not identical or equivalent to any FDA-approved branded medication. Vyvron does not imply any such equivalence."
And the funnel is real. The intake at start.vyvron.com is a genuine clinical questionnaire that asks the patient to accept OpenLoop's telehealth consent by name, and eight jurisdictions are flagged as requiring a scheduled video visit rather than a form alone.
What Vyvron will not tell you
Now the part that is missing, stated precisely, because a vague version of this criticism would be unfair.
Vyvron's site is a React single-page application. Every route, every legal page and every article in its /learn library is served from one JavaScript file: `assets/index-BDGt_Yl6.js`, 483,328 characters, downloaded on August 7, 2026. That file is the site.
Searched across the whole of it, these strings occur zero times: "USP", "sterile", "potency", "tested", "purity", "certificate of analysis", "COA", "503A", "503B", "lot". Three case-insensitive matches for "usp" exist and all three are React's internal `Suspense` symbols.
So this is not a failure to find the testing page. There is no testing claim anywhere in the code that draws the website. Vyvron does not say its preparations are third-party tested, does not name a standard, does not state a potency tolerance, and does not publish a certificate of analysis. It also never states whether its products come from a 503A pharmacy or a 503B outsourcing facility — a distinction that determines what inspection regime applies to the vial in your hand.
The only quality-adjacent language on the site is regulatory-status language: that compounded medications "are not reviewed by the FDA for safety, effectiveness, or quality." That sentence is accurate and Vyvron deserves credit for repeating it. But it describes what has not been checked. It is not a substitute for saying what has.
The gap is sharpest against Vyvron's own library. It has published a guide titled "How to verify a legitimate online GLP-1 provider" and another on what LegitScript certification means. Its pages carry a LegitScript seal under certificate id 50305996. That seal image resolves from LegitScript's CDN; LegitScript's own public checker is reCAPTCHA-gated and returned no certification record when queried, so this review reports the seal as displayed and not as confirmed — neither claimed nor denied.
Sermorelin at $229, and a literature that stopped in 2005
The longevity page sells three injectables. The most expensive question is sermorelin.
Vyvron's tile is short and, on the regulatory facts, correct: "Injectable Sermorelin $229/mo — Physician-prescribed GHRH peptide. Clinician-supervised program. Compounded; not FDA-approved." The programme it sits inside is sold as "[w]ellness and healthy-aging support — options like NAD+, Sermorelin, and B12-MIC — for energy, cellular health, and vitality."
Sermorelin is a growth-hormone-releasing hormone analogue, the 1-29 fragment, and it does prompt the pituitary to release growth hormone. That much is real, and it is why the molecule existed: it was used largely as a diagnostic agent to test whether a pituitary could respond.
As of August 2026, a PubMed search for sermorelin filtered to the randomised-controlled-trial publication type returns 19 records. The newest was published in 2005 — a study of a PEG-conjugated GHRH analogue measuring growth hormone stimulation in healthy young and elderly subjects. 1 Read the other eighteen and the pattern holds: GH response to a challenge, growth in children with GH deficiency, dose-response to a low-dose bolus. Not one measures energy, cellular health or vitality in healthy adults, because that is not what anyone was studying. ClinicalTrials.gov lists 27 sermorelin studies. 2
Twenty-one years is a long time for a field to produce nothing new about the thing being sold.
The other two, and the one that has nothing at all
Injectable NAD+, also $229. As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" combined with an injected route and filtered to randomised controlled trials returns exactly one record: a 2026 placebo-controlled trial in heart failure caused by ischaemic cardiomyopathy. 3 Not energy, not clarity, and not healthy adults. Vyvron makes less of a claim here than most sellers do — the tile is essentially a name, a price and a disclosure — and that restraint is worth acknowledging. It does not change what the buyer is paying for.
Injectable B12-MIC, $145. This is methylcobalamin with methionine, inositol and choline — the "lipotropic" blend that has circulated in weight clinics for decades. A PubMed search for methionine, inositol and choline together, filtered to randomised controlled trials, returns zero records. 4 Searching the trade term instead, lipotropic, returns six randomised trials, and ClinicalTrials.gov lists one study with lipotropic as an intervention. The individual components are each well studied; the injected combination sold under this name has never been through a registered trial.
B12 repletion in a person who is actually deficient is ordinary, effective medicine. That is not what is on sale here. What is on sale is a flat monthly subscription to an injection, to an unselected buyer, for "energy."
Microdosing, which is a marketing word
The third programme is the one worth a paragraph of its own because the framing is clever.
Vyvron sells "Microdose combinations" that "pair low-dose GLP-1 medication with supportive ingredients for metabolic support and energy," positioned as "[a] measured starting point — for those not ready for full-dose treatment."
As of August 2026, a PubMed search combining low-dose, microdose or microdosing with semaglutide, tirzepatide or GLP-1, filtered to randomised controlled trials, returns 22 records. Every one of them concerns dose-ranging or titration inside a programme whose purpose was to reach a therapeutic dose. The low doses in those trials were a stage, not a destination.
Which is why Vyvron's own phrasing is the most defensible version of this product: "a measured starting point" is genuinely what the low arms of those trials were. The tension is that it is sold as an ongoing subscription at $149 every four weeks, with unnamed "supportive ingredients" blended in, and that combination is not a registered intervention anywhere.
What this adds up to
Vyvron has built the disclosure layer that this category usually skips and skipped the one it usually manages. It will tell you it is a marketing company. It will name the medical group. It will label every product compounded and not FDA-approved and decline to call its compounded GLP-1s equivalent to the branded ones. Those are real and they are not common.
Then it sells three injectables whose combined randomised-trial support amounts to one study in heart-failure patients and a sermorelin literature that stopped in 2005, from a pharmacy it will not name, with no published word about sterility, potency or testing of any kind.
The GLP-1 side of this business rests on strong evidence and describes itself accurately. The longevity side rests on mechanism and asks $229 a month for it.
Questions
Frequently asked questions
Does Vyvron say who makes its medication?▾
No. Vyvron names the clinical side of its chain and not the pharmacy side. Its privacy policy states that "[t]elemedicine and clinical services are provided by OpenLoop Health, Inc., OpenLoop Healthcare Partners, PC, and its affiliated medical groups," and the intake form asks you to accept OpenLoop's telehealth consent by name. On the pharmacy the site says only "partner pharmacies" and "a licensed pharmacy fulfills all prescriptions." No pharmacy is named, no licence number is published, and there is no published way to find out who compounded a given vial. The corporate address, 30 N Gould St, Ste N, Sheridan, Wyoming, is a registered-agent suite.
Does Vyvron publish anything about testing its peptides?▾
No, and this was measured rather than assumed. Vyvron's whole site — every route, every legal page, every article — ships in one JavaScript bundle of 483,328 characters, read on August 7, 2026. Across all of it, the strings "USP", "sterile", "potency", "tested", "purity", "certificate of analysis", "COA", "503A", "503B" and "lot" occur zero times. So there is no testing page to find, no standard named, no potency tolerance stated, and no lot report published. The site does correctly repeat that compounded medications are "not reviewed by the FDA for safety, effectiveness, or quality" — which is a statement about what nobody has checked, not about what Vyvron has.
Is there evidence that injectable sermorelin does what Vyvron sells it for?▾
For the mechanism, yes. For the outcomes, no. Sermorelin is a growth-hormone-releasing hormone analogue and it does stimulate pituitary GH release — that is why it existed, largely as a diagnostic agent. As of August 2026 a PubMed search for sermorelin filtered to randomised controlled trials returns 19 records, and the newest was published in 2005: a study of a PEG-conjugated GHRH analogue measuring growth hormone stimulation. Every one of the 19 measures GH secretion, growth in children, or a diagnostic response. None measures energy, cellular health or vitality in healthy adults. ClinicalTrials.gov lists 27 sermorelin studies. This site does not tell you what to take and does not say sermorelin is unsafe — only that the outcomes on the page have not been tested.
What about the NAD+ and B12-MIC injections?▾
Thinner still, in different ways. For injectable NAD+, a PubMed search in August 2026 for "nicotinamide adenine dinucleotide" with an injected route, filtered to randomised trials, returned exactly one record — a 2026 placebo-controlled trial in heart failure caused by ischaemic cardiomyopathy. For B12-MIC, a search for methionine, inositol and choline together among randomised trials returned zero records; searching the trade term "lipotropic" instead returned six trials, and ClinicalTrials.gov listed one study with lipotropic as an intervention. The components of a MIC injection are each individually studied. The injected blend sold under that name has not been through a registered trial.
Is "microdosing" a GLP-1 a recognised treatment?▾
Not as a distinct regimen. As of August 2026, a PubMed search combining low-dose, microdose or microdosing with semaglutide, tirzepatide or GLP-1, filtered to randomised controlled trials, returns 22 records, and all 22 concern dose-ranging or titration within programmes designed to reach a therapeutic dose. Low doses in those trials were a stage on the way up, not an endpoint. Vyvron's own framing — "a measured starting point — for those not ready for full-dose treatment" — is the most accurate description of what the trial evidence supports. It is sold as an ongoing subscription at $149 every four weeks, blended with "supportive ingredients" that are not named, and that combination is not a registered intervention.
Has Vyvron had an FDA warning letter?▾
No match was found. On August 7, 2026 the 113-letter telehealth warning-letter roster was screened for Vyvron and for OpenLoop, the named clinical partner, on full company names rather than fragments. Neither appears. Two bounds on that: the roster covers the telehealth enforcement waves rather than every letter FDA has ever issued, and absence of a letter is not a clean inspection record — pharmacy inspection findings are not published the way warning letters are, and in Vyvron's case the pharmacy is not even named.
Does Vyvron serve my state?▾
For the evaluation, all 50 states plus Washington, D.C. For compounded GLP-1s, 49 states — Mississippi residents are excluded, and Vyvron says they "may be eligible for branded options only." Eight places require a scheduled video visit rather than a questionnaire alone: Arkansas, Delaware, Kansas, Mississippi, New Mexico, Rhode Island, West Virginia and Washington, D.C. Note whose licences these are: Vyvron states it holds no clinical licence itself, so the coverage belongs to OpenLoop's affiliated medical groups and to unnamed partner pharmacies, none of which publishes a licence number through Vyvron.
Glossary
Key terms
503A compounding pharmacy
A state-licensed pharmacy preparing a medicine against a prescription for a named patient. Compounded preparations are not FDA-approved and FDA does not review them for safety, effectiveness or quality. Vyvron never states which category its preparations come from — the strings "503A" and "503B" do not appear anywhere on its site.
GHRH analogue
A molecule shaped like growth-hormone-releasing hormone, which prompts the pituitary to release growth hormone rather than supplying it directly. Sermorelin is the 1-29 fragment. Stimulating the axis is a mechanism; whether that produces an outcome anyone notices is a separate question the trials have to answer.
Lipotropic injection
An injected blend of methionine, inositol and choline, usually with vitamin B12, long used in weight clinics. The individual compounds have literatures of their own; the blend as sold has no registered randomised trial.
Certificate of analysis
A lot-specific laboratory report stating what was tested and what the results were. A seller describing a testing programme and a seller publishing a certificate you can read are making different claims. Vyvron makes neither.
Four-weekly billing
A cycle of 28 days rather than a calendar month, which produces thirteen charges in a year instead of twelve. Vyvron's checkout lines state "per 4 weeks, billed every 4 weeks", while its programmes page prints the same plans with a "/mo" suffix.
Method
How we checked this
Claims read first-party
Every quoted claim was read off Vyvron's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Sources
References
1.Munafo A, Nguyen TX, Papasouliotis O, et al. (2005). Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.. European journal of endocrinology 153(2):249-56. https://pubmed.ncbi.nlm.nih.gov/16061831/
3.Yu X, Xu J, Cao J (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.. American journal of cardiovascular drugs : drugs, devices, and other interventions 26(1):97-106. https://pubmed.ncbi.nlm.nih.gov/40954388/
5.Novo Nordisk A/S (2026). STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity, NCT03548935 — phase 3, completed, enrolment 1,961. Read 2026-08-07. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT03548935
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.